<p>隨着美國市場進入假期縮短的一週，主要股指收盤下跌，科技股領跌，因市場對科技行業資本支出的擔憂加劇。在這種環境下，識別高增長的科技股需要對市場動態有敏鋭的理解，並能夠駕馭可能影響小型公司的經濟指標。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 72 只股票完整列表。</p>
<p>下面我們展示了一些經過篩選的股票。</p>
<h2>MongoDB (MDB)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> MongoDB, Inc. 在全球提供通用數據庫平台，市值為 344.4 億美元。</p>
<p><strong>運營：</strong> 公司的主要收入來源於其數據處理部門，產生了 23.2 億美元的收入。專注於提供通用數據庫平台支持其全球運營。</p>
<p>在動態的科技環境中，MongoDB 展現了強大的財務靈活性和戰略前瞻性。其年收入增長率為 15.7%，超過美國市場的 10.7%，公司正處於明確的上升軌道。最近的股票回購，包括 513,620 股，金額為 1.5101 億美元，彰顯了對其財務健康和未來前景的信心。此外，MongoDB 對創新的承諾在其研發支出趨勢中顯而易見，這對在競爭激烈的科技行業中維持長期增長至關重要。這種對研究的關注不僅推動了產品的提升，也使 MongoDB 在高風險的人工智能和雲領域中佔據了良好的位置，繼續擴大其影響力。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 MongoDB 的動態。</li>
<li>瞭解 MongoDB 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="1046" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 MDB 收入和支出細分</p>
<h2>Intapp (INTA)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Intapp, Inc. 通過其子公司 Integration Appliance, Inc. 在美國、英國及國際市場提供人工智能驅動的解決方案，市值約為 38.9 億美元。</p>
<p><strong>運營：</strong> Integration Appliance, Inc. 是 Intapp 的子公司，主要通過其軟件和編程部門產生收入，收入為 5.2434 億美元。</p>
<p>Intapp 在競爭激烈的科技環境中展現了韌性和適應能力。儘管在 2026 年第一季度報告了 1435 萬美元的淨虧損，較去年同期的 452 萬美元有所增加，但公司預計年收入增長 12%，略高於美國市場平均水平 10.7%。這一預測與其戰略舉措如 Intapp Collaboration 相一致，該舉措與 Microsoft 365 無縫集成，以增強客户參與度和提高 Ostberg Sinclair &amp; Co.等公司的運營效率。此外，Intapp 最近以約 5000 萬美元回購超過一百萬股股票，顯示出對其未來發展軌跡的強烈信心，以及在持續創新和市場擴張中的對股東價值的承諾。</p>
<ul>
<li>點擊這裏深入瞭解 Intapp 的完整分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取 Intapp 過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 INTA 盈利和收入增長</p>
<h2>Krystal Biotech (KRYS)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商業階段的生物技術公司，專注於發現、開發、製造和商業化針對美國高未滿足醫療需求疾病的基因治療，市值為 73.6 億美元。</p>
<p><strong>運營：</strong> Krystal Biotech 通過商業化針對重大未滿足醫療需求疾病的基因治療產生收入，在該領域報告了 3.7316 億美元的收入。公司在生物技術行業內運營，專注於創新和開發，以應對美國的重大健康挑戰。</p>
<p>Krystal Biotech 最近的成就凸顯了其在高增長生物技術領域的戰略定位，第三季度淨收入從去年同期的 2718 萬美元大幅增加至 7937 萬美元，反映出令人印象深刻的年增長。公司的前瞻性舉措體現在其獲得 FDA 授予的 KB801 平台技術認證，增強了其在眼科領域的管道潛力。這與過去一年 279.8% 的盈利激增和預計年收入增長 26.1% 相一致，超過美國市場 10.7% 的預測。這些里程碑不僅突顯了 Krystal 的創新優勢，也預示着在行業進步中強勁的未來前景。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解 Krystal Biotech 的潛力。</li>
<li>通過我們的歷史報告獲取 Krystal Biotech 過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS 截至 2025 年 12 月的收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>在這裏探索我們美國高增長科技和人工智能股票篩選器中的 72 個名稱。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時瞭解您股票的任何重要更新。</li>
<li>通過使用 Simply Wall St 加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
<h2>準備好嘗試不同的方法嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

新美亞電子

PLTR

<p>隨着美國市場迎來假期縮短的一週，主要股指出現下跌，尤其是科技板塊因對資本支出的擔憂而受到影響。識別高增長的科技股票至關重要，其中 Marker Therapeutics、Sanmina 和 Palantir Technologies 等公司顯示出顯著的收入和盈利增長。MongoDB 和 Intapp 因其韌性和戰略舉措而受到關注，而 Krystal Biotech 在生物科技領域表現強勁。報告強調了理解市場動態和經濟指標在投資高增長科技股票中的重要性</p>

<p>As the United States market enters a holiday-shortened week, major stock indexes have closed lower, with technology shares leading declines amid broader concerns about capital expenditures in the tech sector. In this environment, identifying high-growth tech stocks requires a keen understanding of market dynamics and an ability to navigate economic indicators that may impact small-cap companies.</p>
<div class="lb-trans"><p>隨着美國市場進入假期縮短的一週，主要股指收盤下跌，科技股領跌，因市場對科技行業資本支出的擔憂加劇。在這種環境下，識別高增長的科技股需要對市場動態有敏鋭的理解，並能夠駕馭可能影響小型公司的經濟指標。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sanmina</td>
<td>31.01%</td>
<td>33.24%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 72 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 72 只股票完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我們展示了一些經過篩選的股票。</p>
</div><h2>MongoDB (MDB)</h2>
<div class="lb-trans"><h2>MongoDB (MDB)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> MongoDB, Inc. offers a general-purpose database platform globally and has a market capitalization of $34.44 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MongoDB, Inc. 在全球提供通用數據庫平台，市值為 344.4 億美元。</p>
</div><p><strong>Operations:</strong> The company's primary revenue stream is from its data processing segment, which generated $2.32 billion. The focus on providing a general-purpose database platform supports its global operations.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的主要收入來源於其數據處理部門，產生了 23.2 億美元的收入。專注於提供通用數據庫平台支持其全球運營。</p>
</div><p>Amidst a dynamic tech landscape, MongoDB has demonstrated robust financial agility and strategic foresight. With a notable 15.7% annual revenue growth outpacing the US market's 10.7%, the company is on a clear upward trajectory. Recent share buybacks, including 513,620 shares for $151.01 million, underscore confidence in its financial health and future prospects. Additionally, MongoDB's commitment to innovation is evident from its R&amp;D spending trends which are crucial for sustaining long-term growth in the competitive tech sector. This focus on research not only fuels product enhancement but also positions MongoDB well within the high-stakes AI and cloud domains where it continues to expand its footprint.</p>
<div class="lb-trans"><p>在動態的科技環境中，MongoDB 展現了強大的財務靈活性和戰略前瞻性。其年收入增長率為 15.7%，超過美國市場的 10.7%，公司正處於明確的上升軌道。最近的股票回購，包括 513,620 股，金額為 1.5101 億美元，彰顯了對其財務健康和未來前景的信心。此外，MongoDB 對創新的承諾在其研發支出趨勢中顯而易見，這對在競爭激烈的科技行業中維持長期增長至關重要。這種對研究的關注不僅推動了產品的提升，也使 MongoDB 在高風險的人工智能和雲領域中佔據了良好的位置，繼續擴大其影響力。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of MongoDB.</li>
<li>Learn about MongoDB's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 MongoDB 的動態。</li>
<li>瞭解 MongoDB 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/d5712116-04fc-48ef-9efb-47d6667c5ea2/chart/revenue-and-expenses-breakdown"/></p>
<p>MDB Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 MDB 收入和支出細分</p>
</div><h2>Intapp (INTA)</h2>
<div class="lb-trans"><h2>Intapp (INTA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Intapp, Inc., through its subsidiary Integration Appliance, Inc., delivers AI-powered solutions across the United States, the United Kingdom, and internationally with a market cap of approximately $3.89 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Intapp, Inc. 通過其子公司 Integration Appliance, Inc. 在美國、英國及國際市場提供人工智能驅動的解決方案，市值約為 38.9 億美元。</p>
</div><p><strong>Operations:</strong> Integration Appliance, Inc., a subsidiary of Intapp, generates revenue primarily through its software and programming segment, which accounts for $524.34 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Integration Appliance, Inc. 是 Intapp 的子公司，主要通過其軟件和編程部門產生收入，收入為 5.2434 億美元。</p>
</div><p>Intapp, navigating the competitive tech landscape, has shown resilience and adaptability. Despite reporting a net loss of $14.35 million in Q1 2026, an increase from the previous year's $4.52 million, the company is poised for recovery with projected annual revenue growth of 12%, slightly above the US market average of 10.7%. This forecast aligns with its strategic initiatives like Intapp Collaboration which integrates seamlessly with Microsoft 365 to enhance client engagement and operational efficiency for firms like Ostberg Sinclair &amp; Co. Moreover, Intapp's recent repurchase of over a million shares for approximately $50 million signals strong confidence in its future trajectory and commitment to shareholder value amidst ongoing innovations and market expansions.</p>
<div class="lb-trans"><p>Intapp 在競爭激烈的科技環境中展現了韌性和適應能力。儘管在 2026 年第一季度報告了 1435 萬美元的淨虧損，較去年同期的 452 萬美元有所增加，但公司預計年收入增長 12%，略高於美國市場平均水平 10.7%。這一預測與其戰略舉措如 Intapp Collaboration 相一致，該舉措與 Microsoft 365 無縫集成，以增強客户參與度和提高 Ostberg Sinclair &amp; Co.等公司的運營效率。此外，Intapp 最近以約 5000 萬美元回購超過一百萬股股票，顯示出對其未來發展軌跡的強烈信心，以及在持續創新和市場擴張中的對股東價值的承諾。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Intapp.</li>
<li>Review our historical performance report to gain insights into Intapp's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Intapp 的完整分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取 Intapp 過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/9e88ee62-4928-4695-8aee-01cdb51f6526/chart/earnings-and-revenue-growth"/></p>
<p>INTA Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 INTA 盈利和收入增長</p>
</div><h2>Krystal Biotech (KRYS)</h2>
<div class="lb-trans"><h2>Krystal Biotech (KRYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $7.36 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商業階段的生物技術公司，專注於發現、開發、製造和商業化針對美國高未滿足醫療需求疾病的基因治療，市值為 73.6 億美元。</p>
</div><p><strong>Operations:</strong> Krystal Biotech generates revenue by commercializing genetic medicines aimed at treating diseases with significant unmet medical needs, reporting $373.16 million in this segment. The company operates within the biotechnology sector, focusing on innovation and development to address critical health challenges in the U.S.</p>
<div class="lb-trans"><p><strong>運營：</strong> Krystal Biotech 通過商業化針對重大未滿足醫療需求疾病的基因治療產生收入，在該領域報告了 3.7316 億美元的收入。公司在生物技術行業內運營，專注於創新和開發，以應對美國的重大健康挑戰。</p>
</div><p>Krystal Biotech's recent achievements underscore its strategic positioning in the high-growth biotech sector, marked by a robust increase in net income to $79.37 million for Q3 2025 from $27.18 million the previous year, reflecting an impressive annual growth. The company's forward-looking initiatives are evident from its FDA-granted platform technology designation for KB801, enhancing its pipeline potential in ophthalmology. This aligns with a significant 279.8% earnings surge over the past year and an expected revenue growth of 26.1% per annum, surpassing the US market forecast of 10.7%. These milestones not only highlight Krystal's innovative edge but also signal strong future prospects amid industry advancements.</p>
<div class="lb-trans"><p>Krystal Biotech 最近的成就凸顯了其在高增長生物技術領域的戰略定位，第三季度淨收入從去年同期的 2718 萬美元大幅增加至 7937 萬美元，反映出令人印象深刻的年增長。公司的前瞻性舉措體現在其獲得 FDA 授予的 KB801 平台技術認證，增強了其在眼科領域的管道潛力。這與過去一年 279.8% 的盈利激增和預計年收入增長 26.1% 相一致，超過美國市場 10.7% 的預測。這些里程碑不僅突顯了 Krystal 的創新優勢，也預示着在行業進步中強勁的未來前景。</p>
</div><ul>
<li>Take a closer look at Krystal Biotech's potential here in our health report.</li>
<li>Gain insights into Krystal Biotech's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解 Krystal Biotech 的潛力。</li>
<li>通過我們的歷史報告獲取 Krystal Biotech 過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>KRYS 截至 2025 年 12 月的收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Explore the 72 names from our US High Growth Tech and AI Stocks screener here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們美國高增長科技和人工智能股票篩選器中的 72 個名稱。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時瞭解您股票的任何重要更新。</li>
<li>通過使用 Simply Wall St 加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好嘗試不同的方法嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

Exploring High Growth Tech Stocks In The US For December 2025

- 美國主要股指下跌，科技股因資本支出擔憂領跌。  
- 前十大高增長科技公司包括 Marker Therapeutics 和 Palantir Technologies 等。  
- MongoDB 及 Intapp 顯示出強勁的財務成長潛力，尤其在研發和市場擴展方面。

探索 2025 年 12 月美國高增長科技股票